SGLT2 inhibitors reduced the risk of dialysis, transplantation, or death due to kidney disease in individuals with type 2 diabetes and provided protection against acute kidney injury. These data provide substantive evidence supporting the use of SGLT2 inhibitors to prevent major kidney outcomes in people with type 2 diabetes (The Lancet Diabetes & Endocrinology)
Diabetes News
Tag: SGLT2 inhibitors
What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?
There is growing evidence to illustrate the overall safety profile of this class of agents and support the benefit–risk profile of SGLT2 inhibitors as a preferred option following metformin monotherapy failure, with respect to both kidney disease progression and heart failure outcomes (Diabetes Therapy)
Class effects of SGLT2 inhibitors on cardiorenal outcomes
Dapagliflozin, empagliflozin, and canagliflozin have internally and externally consistent and biologically plausible class effects on cardiorenal outcomes. Baseline renal filtration function and degree of albuminuria are the most significant indicators of risk for both CV and renal events. Thus, these two factors also anticipate the greatest clinical benefit for SGLT2i (Cardiovascular Diabetology)
Dapagliflozin vs Non‐SGLT‐2i Treatment is Associated with Lower Hospital Care Costs in Type 2 Diabetes Patients Similar to the DECLARE‐TIMI 58 Participants
In a nationwide, real‐world, DECLARE‐like population, dapagliflozin was associated with lower hospital costs compared with oGLD, mainly as a result of reduced rates of CV‐ and T2D‐associated complications (Diabetes, Obesity and Metabolism)
The future is now: SGLT2 inhibitors and type 1 diabetes – what about exercise?
This novel drug class, which has received wide attention in its glucose-lowering and cardiovascular-protective properties in the management of type 2 diabetes, also bears potential for individuals with T1D who are struggling with achieving glycaemic targets
Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study
In a large cohort of patients seen in routine clinical practice, risk for severe and nonsevere UTI events among those initiating SGLT-2 inhibitor therapy was similar to that among patients initiating treatment with other second-line antidiabetic medications (Annals of Internal Medicine)
The future of new drugs for diabetes management
The future of the newer classes of glucose-lowering drugs, namely dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium/glucose co-transporter-2 (SGLT-2) inhibitors, is being redefined by the large prospective cardiovascular outcome trials (Diabetes Research and Clinical Practice)
Do GLP‐1RAs and SGLT‐2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta‐analysis
Given that black patients with type 2 diabetes were not well represented in CVSTs and such trials were underpowered to evaluate racial differences, it remains unclear whether GLP‐1RAs or SGLT‐2is would reduce cardiovascular risk in such patients, and additional studies targeting black patients are urgently needed (Diabetes, Obesity and Metabolism)
Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes
Low-dose SGLTi profile was the favored adjunct-to-insulin therapy by persons with T1D (Diabetes Care)
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
The Improving Diabetes Steering Committee seeks to support healthcare professionals (HCPs) in appropriate treatment selection for people with T2DM who are at risk of developing or have established CVD and examines the role of SGLT2i therapy for these people. (Diabetes Therapy)
SGLT inhibitors: medications that mimic fasting for cardiovascular prevention
This review proposes a unifying hypothesis to explain the reduction in cardiovascular diseases through three different mechanisms of curbing free fatty acid (FFA) excess, all leading to the common mechanism of cellular caloric restriction. If this hypothesis is correct, the excellent results obtained with SGLT‐2 inhibitors could be attributed to their close simulation of fasting (Diabetes, Obesity and Metabolism)
SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class
Cardiovascular outcomes trials investigating SGLT2 inhibitors have suggested benefits beyond glucose lowering that have been confirmed in real-world evidence studies (BMC Endocrine Disorders)
Lower Renal Threshold for Glucose Reabsorption in Type 1 Diabetes Mellitus (T1DM) May Explain the Smaller Contribution of SGLT2 Inhibitors to the Improvement of Plasma Glucose Control Compared with T2DM
These results indicate that it is advisable to estimate the renal threshold for glucose reabsorption prior to initiating SGLT2 inhibitor therapy in patients with T1DM (Diabetes Therapy)
Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 inhibitors in type 1 diabetes (updated 2019)
The present ABCD position statement is to mitigate this risk and other potential complications in people taking these drugs. Particular caution needs to be exercised in people who are at risk of diabetic ketoacidosis due to low calorie diet, illnesses, injuries, starvation, excessive exercise, excessive alcohol consumption and reduced insulin admin-istration among other precipitating factors for diabetic ketoacidosis (ABCD)
Sodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research
This review provides a physiological perspective to understanding the multiple actions of these drugs complemented by a clinical perspective toward balancing benefits and risks (Diabetes Care)
SGLT Inhibitors for Type 1 Diabetes: Proceed With Extreme Caution
The increase in absolute risk of DKA, even in closely supervised patients participating in clinical trials, raises a serious concern that DKA will be even more common if SGLT inhibitors are used in routine clinical practice by practitioners who do not have the expertise and resources of the clinical trialists to implement the complex recommendations necessary to mitigate risk for DKA (Diabetes Care)
Renal effects of a sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status
Dietary salt intake, in addition to glycaemic control, correlates with changed eGFRMDRD via tofogliflozin. Thus, an appropriate dietary approach to therapy should be considered before treatment of T2D patients with an SGLT2i (Diabetes, Obesity and Metabolism)
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
Adding semaglutide to SGLT-2 inhibitor therapy significantly improves glycaemic control and reduces bodyweight in patients with inadequately controlled type 2 diabetes, and is generally well tolerated (The Lancet Diabetes & Endocrinology)
Type 2 diabetes and the kidney: insights from cardiovascular outcome trials
There is room for optimism that use of SGLT‐2 inhibitors may change the paradigm of the ineluctable progression of DKD (Diabetes, Obesity and Metabolism)
Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials
In type 1 diabetes, sotagliflozin improves glycaemic and non-glycaemic outcomes and reduces hypoglycaemia rate and severe hypoglycaemia. The risk of diabetic ketoacidosis could be minimised by appropriate patient selection and down-titration of the basal insulin dose (BMJ)
- 1
- 2
- 3
- 4
- Next Page »
Glycosmedia is also available as an App: